Know Cancer

or
forgot password


N/A
N/A
80 Years
Not Enrolling
Both
Malignant Neoplasm of Thyroid Stage I, Malignant Neoplasm of Thyroid Stage II

Thank you

Trial Information


Inclusion Criteria:



- papillary or follicular thyroid cancer

- stage 1 or 2 according to TNM system version 6

- surgery and radioiodine treatment

- levothyroxine suppression treatment

Exclusion Criteria:

- cardiopulmonary failure

- liver failure

- renal failure

- pregnancy

- drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin,
amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

TSH

Outcome Time Frame:

3 months

Safety Issue:

Yes

Authority:

Iran: Ethics Committee

Study ID:

METTC

NCT ID:

NCT01341886

Start Date:

April 2010

Completion Date:

April 2011

Related Keywords:

  • Malignant Neoplasm of Thyroid Stage I
  • Malignant Neoplasm of Thyroid Stage II
  • differentiated thyroid cancer
  • THS suppression
  • metformin
  • Neoplasms
  • Thyroid Neoplasms
  • Thyroid Diseases

Name

Location